News

EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023

Our Products

The product portfolio is led by already commercialized Binosto® for the treatment of postmenopausal osteoporosis.

EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines

Freienbach, February 6, 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced ...

Meet the EffRx Team at the 24rd Annual BIO-Europe International Conference from 5-7 November 2018 in Copenhagen

The 24th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe ...

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States

Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced ...
Scroll to Top